ERBB2 and breast carcinoma: Consistent with molecular profiles of the cell lines, in all 10 indications with significant numbers of HER2+ samples, EGFR expression was relatively higher and/or ERBB3 and CDKN1B lower in in comparison to breast cancers (Fig 3B), and these patterns hold for both the HER2+ and HER2- subsets.